당뇨병 관리 기기 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Diabetes Care Devices Market was valued at USD 59.2 billion in 2025 and is estimated to grow at a CAGR of 12.4% to reach USD 188.8 billion by 2035.

Rising diabetes prevalence continues to create strong demand for advanced solutions that support effective disease management and long-term patient care. The global diabetes care devices market is also benefiting from increasing preference for minimally invasive and wearable technologies that improve patient comfort while enabling continuous health monitoring. These medical devices play an essential role in blood glucose monitoring, insulin administration, and overall diabetes management, allowing patients to better manage their condition through improved treatment accuracy and convenience. Growing financial support from both public and private organizations is further accelerating market expansion by encouraging prevention initiatives, early diagnosis programs, and long-term disease management strategies. Investments in digital healthcare infrastructure, wearable technologies, and connected medical devices continue to strengthen the overall diabetes care ecosystem while improving patient access to advanced treatment solutions. Rapid technological innovation remains a key market trend, with manufacturers focusing on developing cost-effective, user-friendly, and highly reliable diabetes care devices that deliver improved clinical performance and support better patient outcomes across diverse healthcare settings.

The devices segment generated USD 40.5 billion in 2025 and is anticipated to reach USD 130.9 billion by 2035, registering a CAGR of 12.6%, supported by increasing adoption of advanced diabetes management technologies. Continuous innovation in glucose monitoring systems and insulin delivery solutions continues to improve treatment precision, simplify disease management, and enhance patient compliance. Growing demand for accurate glucose monitoring and efficient insulin administration is expected to maintain strong growth throughout the forecast period.

The home care segment accounted for USD 26 billion in 2025. Rising emphasis on independent disease management, greater convenience, and long-term treatment efficiency continues to drive demand for home-based diabetes care solutions. The expansion of connected healthcare technologies, remote patient monitoring, and telehealth services has further strengthened this segment by enabling continuous health tracking and seamless communication between patients and healthcare professionals. Increasing preference for minimally invasive, easy-to-use devices is also supporting sustained adoption across home care environments.

North America Diabetes Care Devices Market captured 41.9% share in 2025. Market expansion across the region is being driven by the growing number of individuals living with diabetes and the increasing need for long-term disease management solutions. Rising rates of lifestyle-related health conditions, together with an aging population, continue to expand the patient base, creating sustained demand for advanced diabetes care technologies and connected medical devices.

Major companies operating in the global diabetes care devices market include Abbott Laboratories, ARKRAY, Ascensia Diabetes Care, B. Braun Melsungen, Becton Dickinson and Company, Bionime, DarioHealth, Dexcom, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche, Insulet, Medtronic, Nova Biomedical, Novo Nordisk, Pendiq, LifeScan, Sanofi, Sinocare, Tandem Diabetes Care, and Ypsomed Holding. Companies operating in the diabetes care devices market continue to strengthen their market position by investing heavily in research and development to introduce innovative, connected, and patient-centric solutions. Manufacturers are focusing on integrating digital health technologies, wearable platforms, and advanced data management capabilities to improve treatment outcomes and enhance patient engagement. Product portfolio expansion, continuous technological innovation, and development of minimally invasive devices remain important competitive strategies. Strategic partnerships, regulatory approvals, and broader geographic expansion are also helping companies increase market penetration and strengthen customer reach.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of diabetes across the world
    • 3.2.1.2 Rising technological advancements in diabetes care devices
    • 3.2.1.3 Increasing investments by public and private organizations for diabetes care
    • 3.2.1.4 Increasing demand for minimally invasive and wearable devices
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of diabetes care devices
    • 3.2.2.2 Rigorous regulatory framework
    • 3.2.2.3 Privacy, cybersecurity, and compliance risks in connected devices
  • 3.2.3 Market opportunities
    • 3.2.3.1 Integrated care models combining CGM, insulin delivery, and telehealth
    • 3.2.3.2 AI-enabled decision support and closed-loop insulin automation
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
    • 3.5.2.1 Non-Invasive glucose monitoring technologies
    • 3.5.2.2 Nanotechnology applications
• 3.6 Diabetes epidemiology and disease burden analysis
  • 3.6.1 Regional diabetes prevalence trends
  • 3.6.2 Gestational diabetes prevalence
  • 3.6.3 Complication rates and healthcare costs
• 3.7 Patent landscape analysis for diabetes device innovations
• 3.8 Clinical trial pipeline assessment for emerging technologies
• 3.9 Supply chain risk analysis for key device components
• 3.10 Patient behavior and technology adoption patterns in diabetes care devices
• 3.11 Reimbursement scenario
  • 3.11.1 Coding and reimbursement
  • 3.11.2 Reimbursement policies and public healthcare sector insurance coverage for insulin delivery systems
    • 3.11.2.1 U.S.
    • 3.11.2.2 Europe
• 3.12 Pricing trend analysis
• 3.13 Future market trends
• 3.14 Gap analysis
• 3.15 Impact of AI & Generative AI on the Market (Driven by Primary Research)
• 3.16 Porter's analysis
• 3.17 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis (Driven by Primary Research)
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
  • 4.3.5 LAMEA
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Devices
  • 5.2.1 Blood glucose monitoring devices
    • 5.2.1.1 Self-monitoring blood glucose meters
    • 5.2.1.2 Continuous glucose monitors
  • 5.2.2 Insulin delivery devices
    • 5.2.2.1 Insulin pumps
      • 5.2.2.1.1 Tubed pumps
      • 5.2.2.1.2 Tubeless pumps
    • 5.2.2.2 Pens
      • 5.2.2.2.1 Reusable
      • 5.2.2.2.2 Disposable
    • 5.2.2.3 Other insulin delivery devices
• 5.3 Consumables
  • 5.3.1 Testing strips
  • 5.3.2 Lancets
  • 5.3.3 Pen needles
    • 5.3.3.1 Standard
    • 5.3.3.2 Safety
  • 5.3.4 Syringes
  • 5.3.5 Insulin pump consumables

Chapter 6 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Hospital
• 6.3 Ambulatory surgical centers
• 6.4 Diagnostic centers
• 6.5 Homecare
• 6.6 Other end users

Chapter 7 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 MEA
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Abbott Laboratories
• 8.2 ARKRAY
• 8.3 Ascensia Diabetes Care
• 8.4 B. Braun Melsungen
• 8.5 Becton, Dickinson and Company
• 8.6 Bionime
• 8.7 DarioHealth
• 8.8 Dexcom
• 8.9 Dr. Reddy's Laboratories
• 8.10 Eli Lilly and Company
• 8.11 F. Hoffmann-La Roche
• 8.12 Insulet
• 8.13 LifeScan
• 8.14 Medtronic
• 8.15 Nova Biomedical
• 8.16 Novo Nordisk
• 8.17 Pendiq
• 8.18 Sanofi
• 8.19 Sinocare
• 8.20 Tandem Diabetes Care
• 8.21 Ypsomed Holding